The decrease in morbidity and mortality of patients with chronic forms of ischemic heart disease is the result of conservative treatment

Česká verzia

Authors: L. Kotík
Authors place of work: I. interní klinika Fakultní Thomayerovy nemocnice a IPVZ Praha, přednosta prof. MUDr. Štefan Alušík, CSc.
Published in the journal: Vnitř Lék 2011; 57(5): 497-501
Category: Reviews

Summary

Article presents actual comparison of therapeutic methods for patients with chronic coronary artery disease and their influence on morbidity and mortality. It calls attention to the insufficiently presented fact, that invasive methods, like percutaneous and surgical revascularization, despite great expectations, have not proved to lower morbidity and mortality in large randomized studies. In contrary several groups of drugs proved their efficiency many times. Paradoxically, the cheapest approach, life style intervention, seems to be the most efficient method for prognosis improvement of patients with chronic coronary artery disease.

Key words:
chronic coronary artery disease – invasive and conservative therapy – morbidity and mortality

Zdroje

1. Varnauskas E. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N Engl J Med 1988; 319: 332–337.

2. Detre K, Peduzzi P, Murphy M et al. Effect of bypass surgery on survival in patients in low- and high-risk subgroups delineated by the use of simple clinical variables. Circulation 1981; 63: 1329–1338.

3. Aschermann M, Aschermann O. Perkutánní transluminální koronární angio-plastika – 30. výročí prvního výkonu. Cor Vasa 2007; 49: 241–242.

4. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996; 335: 217–225.

5. Agostoni P, Biondi-Zoccai GL, Abbate A et al. Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. Eur Heart J 2005; 26: 881–889.

6. Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126–2130.

7. Dibra A, Kastrati A, Mehilli J et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663–670.

8. Boden WE, O’Rourke RA, Teo KK et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503–1516.

9. Frye RL, August P, Brooks MM et al. BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360: 2503–2515.

10. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A et al. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet 2009; 373: 911–918.

11. Nakamura Y, Moss AJ, Brown MW et al. Long-term nitrate use may be deleterious in ischemic heart disease: a study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group. Am Heart J 1999; 138: 577–585.

12. Chow CK, Jolly S, Rao-Melacini P et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010; 121: 750–758.

13. Szwed H, Pachocki R, Domzal-Bochenska M et al. Efficacy and tolerance of trimetazidine in combination with one of the antianginal drugs in patients with stable effort angina. Diagnostyka Leczenie Kardiologii 1997; 4: 237–247.

14. Di Napoli P, Di Giovanni P, Gaeta MA et al. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d’Abruzzo Trimetazidine Trial. J Cardiovasc Pharmacol 2007; 50: 585–589.